Home >   Products   >  Advanced Search

Lomitapide
(CAS Number:182431-12-5 Product Number:L0298)

Structure

zoom
Lomitapide
Synonym AEGR-733
Synonym BMS-201038
Synonym N-(2,2,2-Trifluoroethyl)-9-[4-[4-[4'-(trifluoromethyl)-[1,1'-biphenyl]-2-ylcarboxamido]piperidin-1-yl]butyl]-9H-fluorene-9-carboxamide

General Information

Product Number L0298

* Items available from stock in Japan will be delivered in 1-2 weeks.
* Please contact us if you need further information.
(Sales Dept Tel: 800-423-8616 / 503-283-1681 E-mail: Sales-US@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that we cannot offer bulk quantities for some products.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(HPLC)
Storage Temperature 0-10°C
M.F. / M.W. C39H37F6N3O2=693.73
CAS Number 182431-12-5
Related CAS Number
MDL Number MFCD16620494
  • Product Details
  • Safety & Regulations
  • Reference & Application

Specification

Purity(HPLC) min. 98.0 area%
Elemental analysis(Nitrogen) 5.75 to 6.35 %

Data of Reference

mp 142°C(lit.)

References

Reaxys-RN 13754976

Transport Information

HS Number 2933.39.4100

Application

Lomitapide: A Microsomal Triglyceride Transfer Protein (MTP) Inhibitor

Lomitapide (AEGR-733 or BMS-201038) is a microsomal triglyceride transfer protein (MTP) inhibitor. MTP is a lipid transfer protein that resides in the endoplasmic reticulum of hepatocytes and intestinal epithelial cells, and is required for the assembly and secretion of apolipoprotein B (apo B)-containing lipoproteins by the liver and by the intestine. Lomitapide directly binds and inhibits MTP, thereby preventing the assembly of apolipoprotein B-containing lipoproteins in hepatocytes and intestinal epithelial cells. This inhibits the synthesis chylomicros of and very low-density lipoprotein (VLDL). The inhibition of the synthesis of VLDL leads to reduced levels of low-density lipoprotein cholesterol (LDC-C) in plasma. In addition, lomitapide mesylate [CAS: 202914-84-9] is used for clinical. (The product is for research purpose only.)

References

Page Top